Opinion

Video

Donanemab for Treatment of Alzheimer’s Disease

Panelists discuss how the TRAILBLAZER-ALZ-2 trial demonstrates that donanemab significantly reduces amyloid plaques and slows cognitive and functional decline in early Alzheimer’s disease, with a manageable safety profile and the potential for faster plaque removal compared to other amyloid-targeting therapies.

Summary for Physicians

TRAILBLAZER-ALZ-2 Clinical Trial: Donanemab in Early Alzheimer’s Disease

Trial Design:

  • Objective: The TRAILBLAZER-ALZ-2 trial investigated donanemab, a monoclonal antibody targeting amyloid-beta plaques, specifically binding to soluble and insoluble forms of amyloid to promote their removal. It aimed to assess efficacy and safety in patients with early symptomatic Alzheimer’s disease.
  • Population: Participants were early Alzheimer’s patients with mild cognitive impairment (MCI) or mild dementia, and evidence of amyloid plaque on imaging.
  • Methodology:
    • Randomized, double-blind, placebo-controlled design.
    • Patients were administered donanemab (700 mg every 4 weeks) or placebo for 18 months.
    • The primary endpoint was cognitive decline measured by the ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive Subscale).
    • Secondary endpoints included functional decline (measured by CDR-SB), and biomarker analysis (amyloid plaque burden, tau levels, and neurodegeneration markers).

Study Results:

  • Efficacy:
    • Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy.
    • Cognitive Outcomes: Treatment with donanemab led to slower cognitive decline compared to placebo, as measured by ADAS-Cog14 and CDR-SB. The magnitude of effect was similar to that seen with other amyloid-targeting therapies, though donanemab had a slightly higher rate of amyloid clearance.
    • Functional Impact: The trial showed a significant benefit in functional outcomes as well, with patients on donanemab demonstrating slower progression of activities of daily living compared to those on placebo.
  • Safety:
    • ARIA (Amyloid-Related Imaging Abnormalities) were reported, similar to other amyloid-modifying therapies, but occurred in a manageable proportion of patients.
    • Adverse Events: Most adverse events were mild to moderate, with no new significant safety concerns emerging beyond those seen in earlier amyloid-modifying trials (e.g., lecanemab).
    • Discontinuation Rates: Discontinuations due to side effects were relatively low, with most patients tolerating the therapy with appropriate monitoring.

Clinical Implications:

  • Donanemab shows potential as an effective disease-modifying treatment for patients with early-stage Alzheimer’s disease, significantly reducing amyloid plaques and slowing cognitive and functional decline.
  • ARIA management remains essential, requiring regular MRI monitoring for early detection of side effects.
  • The results are comparable to those seen with other amyloid-targeting antibodies (like lecanemab), but donanemab's faster amyloid plaque reduction could offer clinical advantages in slowing disease progression.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
5 experts in this video
5 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.